Revance Therapeutics, Inc.
Revance Therapeutics, Inc. (Revance) is the US based specialty bio-pharmaceutical company. It is engaged in the development of next generation products in dermatology and aesthetic medicine. The company offers TransMTS, a platform technology that enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures. It also has exclusive rights to highly purified botulinum toxin type A (BoNT-A) proteins for use in all dose forms for all indications. The company by using the TransMTS platform is developing RT001, a physician-applied topical BoNT-A product for cosmetic, hyperhidrosis and dermatologic indications; RT002, a next-generation injectable BoNT-A product. Further, to develop additional applications of Botulinum toxin type A utside dermatology and aesthetic medicine, the company is seeking partnerships in various therapeutic areas including orthopedics, neurology and pain management. The company is headquartered in California, the US.